Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in TWST.
← Back to Free Index

TWST

Analysis as of: 2026-07-14
Twist Bioscience Corporation
Twist Bioscience manufactures synthetic DNA products, sequencing workflow tools, and antibody discovery solutions for biopharma, diagnostics, industry, academic, and government customers.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

AI Expands Biology Demand, Valuation Caps Torque
A scaled DNA manufacturing platform should benefit as AI creates more design-build-test cycles across therapeutics and diagnostics. The opportunity is real, but most of the equity case depends on proving premium economics and lower financing dependence rather than just riding higher volume.

Analysis

Thesis
AI should increase the number of biological designs that need to be physically built, tested, and reordered, and Twist owns a scaled DNA manufacturing stack that can absorb that volume; the investment question is not demand creation but whether Twist can convert higher throughput, workflow trust, and better mix into durable premium economics before dilution or pricing pressure erodes the upside.
Last Economy Alignment
Twist benefits when AI makes biological design cheaper because the bottleneck shifts to trusted physical execution. Alignment is strong but capped because value capture still sits mainly in product margin, not software tolls.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
1.7x (from 5 most recent analyses)
Reasoning
The business can plausibly more than double revenue by 2031 if AI-driven design lowers idea cost and pushes more work into DNA synthesis, NGS workflows, and antibody services. But today's valuation already anticipates a lot of success, so shareholder upside likely comes from execution and mix improvement rather than from a higher multiple. That makes the opportunity attractive but not open-ended.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic capture, not lack of demand. Twist likely benefits if AI creates more biological experiments, but shareholders still need proof that volume converts into higher gross margin, durable breakeven, and lower financing dependence. The near-term gates are clear: deliver Q3 revenue, finish FY26 above 52% gross margin, hit Q4 adjusted EBITDA breakeven, avoid meaningful ATM usage, and keep the single-source component from becoming a throughput bottleneck.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.51
They own a DNA factory and the ordering hooks that turn AI-generated designs into real molecules, so cheaper cognition can send more work their way. The risk is that they still get paid mostly per physical order, so if buying DNA becomes a price-only decision the upside stays good but not unbeatable.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$77.70
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case